Mindstrong

Mindstrong is a San Francisco-based neurotechnology company operating at the intersection of digital health and mental health care. The company developed a platform that uses passive digital biomarkers derived from smartphone usage patterns — such as typing speed, scrolling behavior, and screen interactions — to continuously monitor and assess mental health conditions including depression and bipolar disorder. By capturing these subtle behavioral signals through everyday device use, Mindstrong aimed to provide clinicians with objective, real-time data on patient cognitive and emotional states without requiring active input from users. Their platform was designed specifically to support clinical care management for individuals living with serious mental illness, bridging the gap between episodic clinical visits and continuous patient monitoring.

Mindstrong raised $100 million in Series C funding, reflecting significant investor confidence in the company's approach to transforming mental health care delivery through data-driven insights. The company attracted backing from prominent healthcare and venture investors and cultivated partnerships with health systems, payers, and care management organizations focused on high-acuity psychiatric populations. Their work advanced the clinical validation of passive sensing as a legitimate tool for psychiatric monitoring, contributing meaningful research to the field of digital psychiatry. These milestones positioned Mindstrong as one of the more mature and well-capitalized companies working on objective measurement tools for mental health at a time when the sector was gaining broad institutional attention.

Mindstrong represents a critical inflection point in how the neurotechnology industry approaches mental health monitoring and intervention. By demonstrating that clinically meaningful signals could be extracted from everyday smartphone behavior, the company helped establish passive digital biomarkers as a credible category within both neurotech and digital therapeutics. Their work challenged the longstanding reliance on subjective self-reporting in psychiatry, pushing the field toward more continuous and objective methods of assessing neurological and psychological states. For the broader neurotech industry, Mindstrong served as an important proof of concept that consumer-grade devices could serve as powerful instruments for brain and behavior science.